DNP 805 Topic 3 decision support evaluation example

Health Care Informatics Grand Canyon University Free custom sample in 24 to 48h

This DNP 805 Topic 3 sample paper evaluates an interruptive QT-prolongation interaction alert that fired 11,042 times in a quarter at a composite 180-bed hospital and was overridden 91 percent of the time. It forms part of GCU DNP 805, Health Care Informatics, catalog code DNP-805, taken within Grand Canyon University's DNP. Ondansetron pairs account for 47 percent of firings. The override rate is read as evidence about the rule, not clinician noncompliance, with Phansalkar and colleagues and van der Sijs and colleagues as context. The threshold is located in a 118-drug list mixing risk levels, and two specification changes use Tisdale and colleagues' risk factors.

CourseDNP 805 Health Care Informatics
TopicTopic 3
Paper typeClinical decision support evaluation
LengthAbout 960 words, 4 pages
FormatAPA 7 student paper
SchoolGrand Canyon University (GCU)
ProgramDNP
UpdatedOctober 2026

Free sample paper for DNP 805 Topic 3

1

Eleven Thousand Firings, Ninety-One Percent Overridden: Evaluating a QT-Prolongation Interaction Alert and Two Changes to Its Specification

[Author Name]

College of Nursing and Health Care Professions, Grand Canyon University

DNP-805: Health Care Informatics

Topic 3 Assignment

[Instructor Name]

November 23, 2026

The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.

What this page is doingThe title puts the two figures the evaluation turns on at the front, which signals that the override rate is the finding rather than background. The hospital, alert and figures are composites; the sources are real.
2

Eleven Thousand Firings, Ninety-One Percent Overridden: Evaluating a QT-Prolongation Interaction Alert and Two Changes to Its Specification

The Alert and Where It Sits

At a composite 180-bed community hospital, an interruptive drug interaction alert fires when a prescriber orders a medication on the hospital's list of 118 drugs that can prolong the QT interval while the patient already has an active order for another drug on the list. It was built to prevent torsades de pointes, a ventricular arrhythmia that can follow marked QT prolongation. The alert sits in the ordering pathway: it appears when the prescriber signs the order, blocks signing until it is acknowledged and requires an override reason. That placement matters, because an alert that interrupts at signing costs the prescriber time at the moment they are trying to finish.

What the Figures Show

In the third quarter of 2026, the alert fired 11,042 times for 3,610 patients, and it was overridden in 10,048 firings, 91 percent. The most common pair was intravenous ondansetron with another listed drug, which accounted for 47 percent of firings. Override rates differed by service, as Table 1 shows.

Table 1

QT Interaction Alert Firings and Overrides by Prescriber Group, July to September 2026

Prescriber groupFiringsOverriddenOverride rate
Surgery and anesthesia3,9803,86197 percent
Hospital medicine4,4203,97890 percent
Emergency medicine1,8121,57687 percent
Psychiatry consult83063376 percent
All11,04210,04891 percent
What this page is doingThe override rate is reported with its denominator and broken out by group. The pattern of who overrides is what allows the paper to tell a wrong rule from a rule that one service was never consulted about.
3

What the Override Rate Means

A rule that is ignored nine times in ten is either wrong or badly specified, and treating the 91 percent as clinician noncompliance would miss the evidence the overrides themselves provide. High override rates for drug safety alerts are common, with most interaction alerts overridden in published studies (van der Sijs et al., 2006), and the usual explanation is that many alerts are not clinically relevant to the patient in front of the prescriber.

Two failures must be told apart. A rule can be wrong, warning about combinations that rarely cause harm. Or it can be right and badly timed, warning about a real risk at a moment when the prescriber cannot act on it. The distribution in Table 1 points to the first. Overrides are highest in surgery and anesthesia, where single perioperative doses of ondansetron with another listed drug are routine and the risk from a single dose is low, and lowest in psychiatry, where combinations are ongoing and more often clinically meaningful. The override reasons agree: 72 percent of overrides chose "benefit outweighs risk" or "patient monitored," and 18 percent chose "single dose." The alert is overridden most where it is least relevant.

The Threshold Producing the Volume

The specification locates the problem. The rule fires on any pair from the list, and the list includes drugs with a known risk of torsades alongside drugs with only possible or conditional risk. It takes no account of the patient: it fires identically for a healthy 30-year-old receiving one dose of ondansetron before surgery and for an 80-year-old with heart failure, low potassium and a prolonged QTc on two drugs of known risk. Patient factors such as a prolonged QTc on admission, low potassium, loop diuretic use, heart failure and taking more than one QT-prolonging drug predict prolongation in hospitalized patients (Tisdale et al., 2013), and the rule uses none of them. Its threshold was set to catch every theoretical interaction, and it does.

What the Placement Costs

Placement multiplies the cost of a poorly specified rule. Because the alert interrupts at the moment of signing, every firing takes the prescriber out of the task they were finishing, and the override screen requires a reason to be chosen before the order can be signed. Timed on a sample of 50 firings, acknowledging the alert took a median of 14 seconds. Across 11,042 firings, that is about 43 hours of prescriber time in one quarter, most of it spent dismissing warnings that the prescriber had judged irrelevant within a second of seeing them. The larger cost is harder to count: an alert that is almost always irrelevant teaches prescribers to dismiss it without reading, which is the habit that makes the rare relevant firing dangerous.

Two Changes and Their Expected Effects

Change 1: restrict the interruptive alert to pairs in which at least one drug has known risk and the patient either has a QTc of 470 ms or more on the most recent electrocardiogram or has no electrocardiogram in the past 30 days. Pairs outside those criteria would display a noninterruptive notice in the order details instead. Applying these criteria retrospectively to the quarter's firings, the interruptive alert would have fired about 2,900 times, a 74 percent reduction. The expected override rate is about 60 percent, still high but about the combinations and patients most at risk. The target harm, torsades or a QTc above 500 ms after a new combination, should not rise.

Change 2: remove single perioperative doses from the interruptive rule entirely, since they account for most surgical firings, and route the remaining high-risk combinations to the pharmacist verification queue as well as to the prescriber. Some interactions have been identified by expert panels as suitable for noninterruptive display to reduce alert fatigue (Phansalkar et al., 2013). Expected effect: surgical firings fall by about 85 percent, and pharmacists review every high-risk combination whether or not the prescriber overrides.

What this page is doingEach change carries a predicted effect on firing, on override and on the harm the rule targets. A proposal with a prediction can be checked afterward; one without cannot.
4

What Must Be Monitored After Any Change

Four measures, monthly for a year: firings and override rates by service, to confirm the predicted reductions; the number of patients with a new QTc of 500 ms or more after a combination of two listed drugs, from electrocardiogram reports; any torsades events, from the rapid response and event reporting systems; and pharmacist interventions on high-risk combinations. If QTc events rise, the criteria will be widened again. The pharmacy and therapeutics committee will review the figures quarterly.

References

Phansalkar, S., van der Sijs, H., Tucker, A. D., Desai, A. A., Bell, D. S., Teich, J. M., Middleton, B., & Bates, D. W. (2013). Drug-drug interactions that should be non-interruptive in order to reduce alert fatigue in electronic health records. Journal of the American Medical Informatics Association, 20(3), 489-493. https://doi.org/10.1136/amiajnl-2012-001089

Tisdale, J. E., Jaynes, H. A., Kingery, J. R., Mourad, N. A., Trujillo, T. N., Overholser, B. R., & Kovacs, R. J. (2013). Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circulation: Cardiovascular Quality and Outcomes, 6(4), 479-487. https://doi.org/10.1161/CIRCOUTCOMES.113.000152

van der Sijs, H., Aarts, J., Vulto, A., & Berg, M. (2006). Overriding of drug safety alerts in computerized physician order entry. Journal of the American Medical Informatics Association, 13(2), 138-147. https://doi.org/10.1197/jamia.M1809

DNP 805 Topic 3 instructions, in plain terms

Topic 3 in DNP-805 asks students to evaluate a clinical decision support tool in their organization. Strong evaluations describe where the alert sits in the workflow, report its firing and override figures and interpret a high override rate as information about the rule rather than as noncompliance. Students should locate the specification feature producing the volume, explain what the alert's placement costs prescribers and propose specific changes with their expected effects. The evaluation should name the measures that must be monitored after any change, including safety outcomes the original alert was built to prevent, so that reducing alert volume does not quietly remove protection. Real figures from the organization make the evaluation, where they can be obtained.

Inside the DNP 805 Topic 3 example

The finished example evaluates one alert and reports numbers throughout. The rule fires on a drug interaction, it fired eleven thousand times in a quarter, and it was overridden in ninety one percent of those firings. That override rate is treated as the finding rather than as background, because a rule ignored nine times in ten is either wrong or badly specified. The example examines the specification and locates the problem in a threshold set to catch every theoretical interaction rather than the clinically meaningful ones. Architecture appears only where it explains something: the rule sits in the ordering pathway, so it interrupts at the point of maximum cost. Two changes are proposed, each with the expected effect on both firing and override.

Where the marks sit in the DNP 805 Topic 3 rubric

Faculty reward an override rate read as evidence. An Excellent evaluation reports 11,042 firings for 3,610 patients and a 91 percent override rate, with ondansetron pairs at 47 percent. Credit goes to locating the cause in a list mixing known, possible and conditional risk drugs, and to the cost of an interruptive alert at signing. The rubric values two changes, restricting interruption to known-risk pairs with a long QTc or no recent electrocardiogram, with predicted effects. Top marks go to four monitored measures, including torsades events and new QTc values over 500 ms.

DNP 805 Topic 3 help before you submit

Papers describing what decision support is, without evaluating any instance of it, are the version that gets least credit at doctoral level. A second failure is reporting an override rate and treating it as clinician non compliance, when a rule ignored in the great majority of cases has usually specified something too broadly. Marks also go for proposing changes with no predicted effect attached, since a proposal nobody can check afterward commits to nothing. Evaluations that ignore where the alert sits in the workflow miss the reason it costs what it does. Firing counts given without a denominator cannot be judged. Recommendations with no monitoring plan leave the organization unable to tell whether the change helped.

Get a DNP-805 Topic 3 example written to your instructions

Send the DNP-805 Topic 3 instructions and the rubric your classroom posts, with the system or alert your section assigned. We write a custom example to those criteria, evaluating one tool on firing and override figures, with the specification examined and changes carrying predicted effects, in 24 to 48 hours. The first is free.

More DNP 805 papers and DNP samples

DNP 805 Topic 3 questions, answered

What does a high override rate actually tell me?

That the rule and the work have come apart, and the rule is the more likely culprit. A warning overridden nine times in ten is either firing on situations clinicians correctly judge to be safe, or arriving at a moment when acting on it is impossible. Treating it as a compliance problem addresses the wrong half of the system.

Do I need real data to evaluate an alert?

Real figures make the paper, and most organizations already hold them, since firing and override counts are standard reports. Where you cannot obtain them, construct plausible ones and say clearly that they are constructed. What does not work is evaluating an alert qualitatively, because the whole argument depends on the ratio between firing and acting.

How much architecture should the paper cover?

Only what explains the finding. Where the rule sits in the ordering pathway matters because it determines what an interruption costs. A general description of record architecture, disconnected from the alert being evaluated, fills pages without supporting anything. Bring in the structure at the point where it accounts for behavior.

Where can I find a free DNP 805 Topic 3 sample paper?

The alert evaluation for DNP 805 Topic 3 covers the alert and its placement, the figures, what the override rate means, the threshold behind the volume, what placement costs, two changes and what must be monitored. Post your DNP 805 Topic 3 prompt and get a free evaluation.

What should be monitored after changing the alert in DNP 805 Topic 3?

Firings and override rates by service, new QTc values of 500 ms or more after two listed drugs, any torsades events and the noninterruptive display's use, each monthly for a year.